title: Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
abstract: This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias. Abnormal cardiac T2* values determined changes in treatment in most subjects. Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias. The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk. Compliance with treatment had a more remarkable role.
authors.affiliation: Clinica Pediatrica 2, Ospedale Regionale per le Microcitemie, ASL 8 Cagliari, Cagliari, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Origa
authors.forename: Fabrice
authors.initials: F
authors.lastname: Danjou
authors.forename: Stefano
authors.initials: S
authors.lastname: Cossa
authors.forename: Gildo
authors.initials: G
authors.lastname: Matta
authors.forename: Patrizio
authors.initials: P
authors.lastname: Bina
authors.forename: Carlo
authors.initials: C
authors.lastname: Dessì
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Defraia
authors.forename: Maria L
authors.initials: ML
authors.lastname: Foschini
authors.forename: Giovanbattista
authors.initials: G
authors.lastname: Leoni
authors.forename: Maddalena
authors.initials: M
authors.lastname: Morittu
authors.forename: Renzo
authors.initials: R
authors.lastname: Galanello
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001145:Arrhythmias, Cardiac / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use; D015913:Chelation Therapy / Q000379:methods*; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007501:Iron / Q000032:analysis; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019190:Iron Overload / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D008279:Magnetic Resonance Imaging; D008297:Male; D009206:Myocardium / Q000737:chemistry / Q000473:pathology*; D010349:Patient Compliance; D011237:Predictive Value of Tests; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use; D012372:ROC Curve; D012306:Risk; D012494:Sampling Studies; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine; D000077588:Deferasirox
keywords: arrhythmia; beta thalassaemia major; compliance; heart failure; heart magnetic resonance imaging